查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1828121

2025年血液學和腫瘤學檢測全球市場報告

Hemato Oncology Testing Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，血液學和腫瘤學檢測市場快速擴張，規模從2024年的35億美元成長至2025年的39.3億美元，複合年成長率達12.5%。預測期內的成長歸因於癌症發生率的上升、意識提升的提高和篩檢項目的推進、醫療保健支出的增加、個人化醫療的普及以及血液病患病率的上升。

預計未來幾年血液學和腫瘤學檢測市場將快速成長，到2029年將達到67.6億美元，年複合成長率（CAGR）為14.5%。預測期內的成長可歸因於個人化醫療趨勢、人工智慧的整合、人口老化、基因組學研究的進步以及對早期癌症檢測需求的不斷成長。預測期內的主要趨勢包括基因組學檢測的技術進步、用於非侵入性檢測的液態切片、行業合作與夥伴關係、監管格局和標準化以及技術進步。

血液腫瘤學檢查包括用於識別血液疾病和血癌症狀的診斷程序。這些檢查在診斷貧血、感染疾病、血友病、血液凝固障礙和白血病等疾病方面發揮重要作用。

與血液學和腫瘤學檢測相關的主要產品和服務包括檢測試劑套件、試劑及相關服務。檢測試劑套件和試劑包括用於分析特定物質的儀器和化學品。檢測程序涵蓋多種癌症類型，包括白血病、淋巴瘤、多發性骨髓瘤等。這些檢測採用的技術包括聚合酵素鏈鎖反應(PCR)、免疫組織化學 (IHC)、新一代定序 (NGS) 和其他先進技術。血液學和腫瘤學檢測的最終用戶包括醫院、學術研究機構和其他醫療保健組織。

2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備行業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰使情況更加複雜，因為由於關稅而更換供應商通常需要重新認證醫療設備，導致市場進入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供血液腫瘤檢測市場統計數據，例如全球市場規模、區域佔有率、血液腫瘤檢測市場佔有率的競爭對手、詳細的血液腫瘤檢測細分市場、市場趨勢以及血液腫瘤檢測行業的商機，為您提供在血液腫瘤檢測行業取得成功所需的數據。本血液腫瘤檢測市場研究報告全面概​​述了您所需的一切，並詳細分析了該行業的現狀和未來前景。

未來五年的預測成長率為14.5%，較我們先前對該市場的預測略有下降0.1%。這一下降主要源自於美國與其他國家之間關稅的影響。這種影響可能會直接影響美國，導致來自印度和愛爾蘭等主要地區的流式細胞技術抗體和微量殘存疾病檢測套件的供應鏈中斷，從而導致白血病診斷延遲和血液病理實驗室成本增加。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響，這種影響也將更加廣泛地顯現。

預計血癌發生率的上升將推動血液腫瘤檢測市場的成長。血液腫瘤涵蓋一組影響血液、骨髓和淋巴系統的血源性癌症，包括白血病、淋巴瘤和骨髓瘤。這些疾病的早期診斷至關重要，而血液腫瘤檢測在這方面發揮著至關重要的作用。例如，美國癌症協會預測，到2023年，白血病將影響約59,610名美國，並造成23,710人死亡。此外，非何傑金氏淋巴瘤預計將影響美國80,550人，並導致20,180人死亡。因此，血癌盛行率的上升是推動血液腫瘤檢測市場向前發展的關鍵因素。

預計未來幾年，不斷成長的醫療保健支出將推動血液腫瘤檢測市場的成長。醫療保健支出是指特定時期內，特定地區、國家或經濟體分配給醫療保健部門的公共和私人資金總額。將這些資金合理分配給血液腫瘤檢測，將有助於提高診斷準確性，實現個人化治療方法，並改善複雜血液腫瘤領域的患者預後。例如，英國國家統計局2024年5月的報告顯示，2022年至2023年，醫療保健總支出名義上增加了5.6%。因此，不斷成長的醫療保健支出正在推動血液腫瘤檢測市場的成長。

血液腫瘤學檢測市場的主要企業正在推出新的創新技術，例如次世代定序儀(NGS)，以提高基因分析的準確性和速度，實現對骨髓惡性腫瘤的全面分析，並支持根據個別患者需求量身定做的個人化治療策略。 NGS 是一種高通量 DNA 定序技術，可快速且經濟高效地分析整個基因組或特定 DNA 區域。例如，2024 年 10 月，專門從事癌症診斷和基因組檢測的美國公司 NeoGenomics Inc. 推出了 AML Express，這是一種下一代定序工具，旨在快速檢測與急性骨髓性白血病(AML) 相關的突變。這個先進的診斷平台提供高精度和快速的周轉時間，幫助腫瘤科醫師及時做出有針對性的治療決策。 AML Express 旨在透過提供與急性骨髓性白血病相關的特定基因圖譜的準確突變見解來改善患者預後。

血液腫瘤學檢測市場的主要企業正在採取策略聯盟的方式，以補充其血液腫瘤學產品組合。策略夥伴關係關係旨在利用彼此的優勢和資源，實現通用利益和成功。例如，施維雅實驗室 (Servier Laboratories) 與凱傑公司 (QIAGEN NV) 合作開發 mIDH1 伴隨診斷檢測。該檢測旨在透過基於 PCR 的診斷檢測快速識別攜帶 IDH1 基因突變的患者，從而補充施維雅的 AML 治療方案。總部位於德國的分子診斷公司凱傑公司 (QIAGEN) 將根據一項主合作協議開發和檢驗該檢測。

2023年1月，美國領先的製藥公司默克公司（Merck & Co. Inc.）收購了Imago BioSciences, Inc.，後者是一家專注於血液腫瘤檢測、診斷以及相關血液疾病治療的生物技術公司。此次收購符合默克公司致力於透過投資創新解決方案和增強產品線來加強其在血液學領域的影響力的承諾。

血液學和腫瘤學檢測市場的主要企業包括 F. Hoffmann-La Roche Ltd.、Abbott Laboratories、Thermo Fisher Scientific Inc.、Illumina Inc.、Invivoscribe Inc.、Qiagen NV、Bio-Rad Laboratories Inc.、Archerdx Inc.、ARUP Laborator Inc.、Bio-Rad Laboratories Inc.、Archerdx Inc.、ARUP Laborator Inc.、Airectm. Inc.、CORE Diagnostics Inc.、Genoptix Inc.、GenPath Diagnostics、NeoGenomics Laboratories Inc.、西門子股份公司、Sysmex Corporation、Laboratory Corporation of America Holdings、安捷倫科技、丹納赫公司、Grifols SA、Diaorin SpA、HTG Molecular Diagnostics Inc. 和 Adaonos Health. 和 Adaoecular Diaga Health。

2024年，北美是血液腫瘤檢測市場最大的地區。預計亞太地區將成為預測期內血液腫瘤檢測全球市場報告中成長最快的地區。血液腫瘤檢測市場報告涵蓋亞太地區、西歐、中歐和東歐、北美、南美以及中東和非洲。

血液學和腫瘤學檢測市場報告涵蓋的國家：澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國、美國、加拿大、義大利、西班牙

血液腫瘤學檢測市場由提供採樣和診斷服務的營業單位所獲得的收益所構成。市場規模包括服務供應商銷售的或包含在其服務產品中的相關商品的價值。血液腫瘤學檢測市場還包括用於提供血液腫瘤學檢測服務的耗材和設備的銷售。該市場的價值是指“出廠價”，即商品製造商或生產商銷售給其他營業單位（包括下游製造商、批發商、經銷商和零售商）或直接銷售給最終客戶的商品價值。該市場中的商品價值也包括商品製造商銷售的相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球血液學和腫瘤學檢測：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球血液學和腫瘤學檢測市場：成長率分析
  • 全球血液學和腫瘤學檢測市場表現：規模與成長，2019-2024
  • 全球血液學和腫瘤學檢測市場預測：規模與成長，2024-2029 年，2034 年
  • 全球血液學和腫瘤學檢測：總目標市場（TAM）

第6章 市場細分

  • 全球血液學及腫瘤學檢測市場（依產品及服務、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 檢測套件和試劑
  • 服務
  • 全球血液學和腫瘤學檢測市場（按癌症類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
  • 其他
  • 全球血液學和腫瘤學檢測市場（按技術、性能和預測），2019-2024 年、2024-2029 年和 2034 年
  • 聚合酵素鏈鎖反應（PCR）
  • 免疫組織化學（IHC）
  • 下一代定序（NGS）
  • 其他
  • 全球血液學和腫瘤學檢測市場（按最終用戶、績效和預測），2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 學術研究機構
  • 其他
  • 全球血液學和腫瘤學檢測市場：檢測試劑套件和試劑細分，按類型、性能和預測，2019-2024 年、2024-2029 年、2034 年
  • PCR套件
  • 次世代定序 (NGS)套件
  • 流式細胞技術試劑
  • ELISA套件
  • 抗體
  • 全球血液學和腫瘤學檢測市場：服務細分、類型、表現和預測，2019-2024 年、2024-2029 年、2034 年
  • 測試服務
  • 諮詢服務
  • 數據分析服務

第7章 區域和國家分析

  • 全球血液學和腫瘤學檢測市場：2019-2024 年、2024-2029 年和 2034 年區域表現和預測
  • 全球血液學和腫瘤學檢測市場：國家、績效及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 血液學和腫瘤學檢測市場：競爭格局
  • 血液學和腫瘤學檢測市場：公司簡介
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Illumina Inc.
    • Invivoscribe Inc.

第31章：其他領先和創新企業

  • Qiagen NV
  • Bio-Rad Laboratories Inc.
  • Archerdx Inc.
  • ARUP Laboratories Inc.
  • Asuragen Inc.
  • Adaptive BIoTechnologies Corp.
  • Cepheid Inc.
  • EntroGen Inc.
  • CORE Diagnostics Inc.
  • Genoptix Inc.
  • GenPath Diagnostics
  • NeoGenomics Laboratories Inc.
  • Siemens AG
  • Sysmex Corporation
  • Laboratory Corporation of America Holdings

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第35章：市場潛力大的國家與策略

  • 2029 年血液學和腫瘤學檢測市場：提供新機會的國家
  • 2029 年血液學和腫瘤學檢測市場：細分市場將帶來新機會
  • 2029 年血液學和腫瘤學檢測市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r24190u

Hemato-oncology testing involves diagnostic procedures designed to identify symptoms of blood disorders and blood cancers. These tests play a crucial role in diagnosing conditions such as anemia, infections, hemophilia, blood-clotting disorders, and leukemia.

The primary products and services associated with hemato-oncology testing include assay kits, reagents, and testing services. Assay kits and reagents encompass instruments and chemicals utilized together to analyze specific substances. The testing procedures cover various cancer types, including leukemia, lymphoma, multiple myeloma, and others. The technologies employed for these tests include polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and other advanced techniques. The end-users of hemato-oncology testing include hospitals, academic and research institutes, and other healthcare entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The hemato oncology testing market research report is one of a series of new reports from The Business Research Company that provides hemato oncology testing market statistics, including hemato oncology testing industry global market size, regional shares, competitors with hemato oncology testing market share, detailed hemato oncology testing market segments, market trends, and opportunities, and any further data you may need to thrive in the hemato oncology testing industry. This hemato oncology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hemato oncology testing market size has grown rapidly in recent years. It will grow from $3.5 billion in 2024 to $3.93 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to increasing cancer incidence, growing awareness and screening programs, rising healthcare expenditure, increasing adoption of personalized medicine, and increasing incidence of blood disorders.

The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $6.76 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to personalized medicine trends, integration of artificial intelligence, rising geriatric population, advancements in genomic research, and rising demand for early cancer detection. Major trends in the forecast period include technological advancements in genomic testing, liquid biopsy for non-invasive testing, collaborations and partnerships in the industry, regulatory landscape and standardization, and technological advancements.

The forecast of 14.5% growth over the next five years indicates a slight reduction of 0.1% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for flow cytometry antibodies and minimal residual disease assay kits, sourced from key regions such as India and Ireland, which could lead to slower leukemia diagnosis and increased hematopathology laboratory costs.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in the incidence of hematologic cancer is set to be a driving force behind the growth of the hemato-oncology testing market. Hematologic cancer encompasses a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including conditions such as leukemia, lymphoma, and myeloma. Early diagnosis is crucial for these diseases, and hemato-oncology testing plays a pivotal role in achieving this. As an illustration, the American Cancer Society estimates that in 2023, leukemia is expected to impact approximately 59,610 Americans, leading to 23,710 deaths. Additionally, non-Hodgkin lymphoma is projected to affect 80,550 individuals in the United States, resulting in 20,180 deaths. Hence, the increasing prevalence of hematologic cancers is a significant driver propelling the hemato-oncology testing market forward.

The increasing healthcare expenditure is projected to drive the growth of the hemato-oncology testing market in the coming years. Healthcare expenditure refers to the total funds, both public and private, allocated to the healthcare sector within a specific geographical area, country, or economy over a defined period. Proper allocation of these funds towards hemato-oncology testing enhances diagnostic accuracy, enables personalized treatment approaches, and improves patient outcomes in the complex field of hematopoietic tumors. For example, a report from the Office for National Statistics, a UK-based government department, revealed in May 2024 that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a growth of only 0.9% in 2022. Therefore, the rise in healthcare expenditure is fueling the growth of the hemato-oncology testing market.

Key companies in the hemato-oncology testing market are implementing new innovations such as next-generation sequencing (NGS) to enhance the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and support personalized treatment strategies tailored to the needs of individual patients. NGS is a high-throughput DNA sequencing technology that facilitates rapid and cost-effective analysis of entire genomes or specific DNA regions. For example, in October 2024, NeoGenomics Inc., a U.S.-based company specializing in cancer diagnostics and genomic testing, launched AML Express, a next-generation sequencing tool designed for the swift detection of mutations related to Acute Myeloid Leukemia (AML). This advanced diagnostic platform provides high accuracy and quick turnaround times, assisting oncologists in making timely and targeted treatment decisions. AML Express aims to enhance patient outcomes by delivering precise mutation insights tailored to the specific genetic profiles associated with AML.

Major companies in the hemato-oncology testing market are adopting a strategic partnership approach to supplement their hemato-oncology portfolio. Strategic partnerships involve leveraging mutual strengths and resources to achieve shared benefits and success. An instance of this is the collaboration between Servier Laboratories and QIAGEN N.V. to develop an mIDH1 companion diagnostic test. This test is intended to complement Servier's AML therapies by swiftly identifying patients with IDH1 gene mutations using a PCR-based diagnostic test. QIAGEN, a Germany-based molecular diagnostics company, will develop and validate this test under the Master Cooperation Agreement.

In January 2023, Merck & Co. Inc., a leading US-based pharmaceutical company, acquired Imago BioSciences, Inc., a biotechnology company focusing on diagnostic and therapeutic products for hemato-oncology testing and related blood disorders. This acquisition aligns with Merck's commitment to fortify its presence in the hematology field by investing in innovative solutions and strengthening its pipeline.

Major companies operating in the hemato oncology testing market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health

North America was the largest region in the hemato oncology testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hemato oncology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hemato oncology testing market consists of revenues earned by entities by providing sampling and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemato-oncology testing market also includes the sales of consumables and instruments which are used to provide hemato-oncology testing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemato Oncology Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hemato oncology testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemato oncology testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemato oncology testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product And Services: Assay Kits And Reagents; Services
  • 2) By Cancer Type: Leukemia; Lymphoma; Multiple Myeloma; Other Cancers
  • 3) By Technology: Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); Next-Generation Sequencing (NGS); Other Technologies
  • 4) By End User: Hospitals; Academic And Research Institutes; Other End Users
  • Subsegments:
  • 1) By Assay Kits And Reagents: PCR Kits; Next-Generation Sequencing (NGS) Kits; Flow Cytometry Reagents; ELISA Kits; Antibodies
  • 2) By Services: Testing Services; Consultation Services; Data Analysis Services
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Illumina Inc.; Invivoscribe Inc.; Qiagen N.V.; Bio-Rad Laboratories Inc.; Archerdx Inc.; ARUP Laboratories Inc.; Asuragen Inc.; Adaptive Biotechnologies Corp.; Cepheid Inc.; EntroGen Inc.; CORE Diagnostics Inc.; Genoptix Inc.; GenPath Diagnostics; NeoGenomics Laboratories Inc.; Siemens AG; Sysmex Corporation; Laboratory Corporation of America Holdings; Agilent Technologies; Danaher Corporation; Grifols SA; Diaorin SpA; HTG Molecular Diagnostics Inc.; Admera Health
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hemato Oncology Testing Market Characteristics

3. Hemato Oncology Testing Market Trends And Strategies

4. Hemato Oncology Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Hemato Oncology Testing Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Hemato Oncology Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Hemato Oncology Testing Market Growth Rate Analysis
  • 5.4. Global Hemato Oncology Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Hemato Oncology Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Hemato Oncology Testing Total Addressable Market (TAM)

6. Hemato Oncology Testing Market Segmentation

  • 6.1. Global Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Assay Kits And Reagents
  • Services
  • 6.2. Global Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Other Cancers
  • 6.3. Global Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Next-Generation Sequencing (NGS)
  • Other Technologies
  • 6.4. Global Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Academic And Research Institutes
  • Other End Users
  • 6.5. Global Hemato Oncology Testing Market, Sub-Segmentation Of Assay Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR Kits
  • Next-Generation Sequencing (NGS) Kits
  • Flow Cytometry Reagents
  • ELISA Kits
  • Antibodies
  • 6.6. Global Hemato Oncology Testing Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Testing Services
  • Consultation Services
  • Data Analysis Services

7. Hemato Oncology Testing Market Regional And Country Analysis

  • 7.1. Global Hemato Oncology Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Hemato Oncology Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hemato Oncology Testing Market

  • 8.1. Asia-Pacific Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hemato Oncology Testing Market

  • 9.1. China Hemato Oncology Testing Market Overview
  • 9.2. China Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hemato Oncology Testing Market

  • 10.1. India Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hemato Oncology Testing Market

  • 11.1. Japan Hemato Oncology Testing Market Overview
  • 11.2. Japan Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hemato Oncology Testing Market

  • 12.1. Australia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hemato Oncology Testing Market

  • 13.1. Indonesia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hemato Oncology Testing Market

  • 14.1. South Korea Hemato Oncology Testing Market Overview
  • 14.2. South Korea Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hemato Oncology Testing Market

  • 15.1. Western Europe Hemato Oncology Testing Market Overview
  • 15.2. Western Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hemato Oncology Testing Market

  • 16.1. UK Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hemato Oncology Testing Market

  • 17.1. Germany Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hemato Oncology Testing Market

  • 18.1. France Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hemato Oncology Testing Market

  • 19.1. Italy Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hemato Oncology Testing Market

  • 20.1. Spain Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hemato Oncology Testing Market

  • 21.1. Eastern Europe Hemato Oncology Testing Market Overview
  • 21.2. Eastern Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hemato Oncology Testing Market

  • 22.1. Russia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hemato Oncology Testing Market

  • 23.1. North America Hemato Oncology Testing Market Overview
  • 23.2. North America Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hemato Oncology Testing Market

  • 24.1. USA Hemato Oncology Testing Market Overview
  • 24.2. USA Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hemato Oncology Testing Market

  • 25.1. Canada Hemato Oncology Testing Market Overview
  • 25.2. Canada Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hemato Oncology Testing Market

  • 26.1. South America Hemato Oncology Testing Market Overview
  • 26.2. South America Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hemato Oncology Testing Market

  • 27.1. Brazil Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hemato Oncology Testing Market

  • 28.1. Middle East Hemato Oncology Testing Market Overview
  • 28.2. Middle East Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hemato Oncology Testing Market

  • 29.1. Africa Hemato Oncology Testing Market Overview
  • 29.2. Africa Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hemato Oncology Testing Market Competitive Landscape And Company Profiles

  • 30.1. Hemato Oncology Testing Market Competitive Landscape
  • 30.2. Hemato Oncology Testing Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Invivoscribe Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hemato Oncology Testing Market Other Major And Innovative Companies

  • 31.1. Qiagen N.V.
  • 31.2. Bio-Rad Laboratories Inc.
  • 31.3. Archerdx Inc.
  • 31.4. ARUP Laboratories Inc.
  • 31.5. Asuragen Inc.
  • 31.6. Adaptive Biotechnologies Corp.
  • 31.7. Cepheid Inc.
  • 31.8. EntroGen Inc.
  • 31.9. CORE Diagnostics Inc.
  • 31.10. Genoptix Inc.
  • 31.11. GenPath Diagnostics
  • 31.12. NeoGenomics Laboratories Inc.
  • 31.13. Siemens AG
  • 31.14. Sysmex Corporation
  • 31.15. Laboratory Corporation of America Holdings

32. Global Hemato Oncology Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hemato Oncology Testing Market

34. Recent Developments In The Hemato Oncology Testing Market

35. Hemato Oncology Testing Market High Potential Countries, Segments and Strategies

  • 35.1 Hemato Oncology Testing Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Hemato Oncology Testing Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Hemato Oncology Testing Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer